EXPERT VIEW

BLISTERS, BONDS AND BIOLOGICS: HOW TO ACHIEVE STABILITY OF DRY POWDER BIOLOGICS

Heather Jameson and Dave Farrow cover the challenging formulation science required to develop a viable dry powder aerosol and examine the inhaler device requirements necessary to protect the formulation throughout its shelf life while also ensuring consistent, high-performance delivery.

SHIELDED THERAPEUTICS: COULD POLYMERIC NANOPARTICLES SAFEGUARD A NEW GENERATION OF INHALED DRUGS?

Kamaal de Silva and Ethan Miller provide an overview of the benefits of polymeric nanoparticles in pulmonary drug delivery and their potential to overcome key challenges in respiratory medicine, while summarising the range of pulmonary delivery devices that could benefit from their use.

MEETING THE DEMAND FOR PATIENT CENTRICITY WITH NASAL SPRAY REPOSITIONING

MEETING THE DEMAND FOR PATIENT CENTRICITY WITH NASAL SPRAY REPOSITIONING

Eric Kaneps discusses key emerging drug delivery trends poised to help the pharmaceutical industry meet the growing demand for patient-centric solutions, with a particular focus on nasal drug delivery, as the nasal spray repositioning of existing drugs offers a range of benefits, including rapid onset of action, improved bioavailability and ease of administration for patients.

GENE THERAPY IN OPHTHALMOLOGY: ADVANCES AND CHALLENGES

GENE THERAPY IN OPHTHALMOLOGY: ADVANCES AND CHALLENGES

Joe Batley and Lorna Barron provide an overview of the latest cutting-edge ophthalmic delivery methods and discuss possible future developments.

REVOLUTIONISING EYE CARE: THE POTENTIAL OF ANTISENSE OLIGONUCLEOTIDES

REVOLUTIONISING EYE CARE: THE POTENTIAL OF ANTISENSE OLIGONUCLEOTIDES

Binbin Tian discusses antisense oligonucleotides and considers their potential as treatments for genetic and multifactorial ophthalmic diseases previously considered untreatable. The article considers how these therapies function as treatments, their current state of development, challenges in their delivery and the evolving regulatory landscape

DRUG DELIVERY TRENDS FOR 2025

DRUG DELIVERY TRENDS FOR 2025

Tom Oakley and Alex Vasiev look back at how the trends anticipated for 2024 played out in reality and look forward to four major trends expected to influence the drug delivery industry in 2025.

FROM PLATFORM TO PRODUCT: ACCELERATING TIME-TO-MARKET FOR PLATFORM TECHNOLOGIES

FROM PLATFORM TO PRODUCT: ACCELERATING TIME-TO-MARKET FOR PLATFORM TECHNOLOGIES

Fran Pencliffe explores the benefits of platform devices for parenteral delivery and outlines the challenges, risks and best practices when bringing a combination product to market in this way.

ELEVATING DIGITAL PATIENT SUPPORT: NOTHING MATTERS UNLESS IT CHANGES BEHAVIOUR

ELEVATING DIGITAL PATIENT SUPPORT: NOTHING MATTERS UNLESS IT CHANGES BEHAVIOUR

Ben Cox, Thomas Grant and Lara Zaki discuss the role of behaviour design in onboarding for self-injection devices and how a robust and balanced framework can enhance the patient experience, reduce injection errors and promote safe and effective use.

NEXT-GENERATION AUTOINJECTORS: BALANCING PATIENTS, PHARMA, PAYERS AND PLANET

NEXT-GENERATION AUTOINJECTORS: BALANCING PATIENTS, PHARMA, PAYERS AND PLANET

David Latham, Matthew Allen and Charlie Dean use a case study of a reusable electromechanical autoinjector to outline the novel product development approach needed to achieve better outcomes for patients, pharma, payers and the planet.

CUSTOM INTEGRATED CIRCUITS ENABLING ADVANCEMENTS IN IMPLANTABLE DRUG DELIVERY SYSTEMS

Dr Asheesh Divetia

CUSTOM INTEGRATED CIRCUITS ENABLING ADVANCEMENTS IN IMPLANTABLE DRUG DELIVERY SYSTEMS

Asheesh Divetia looks at how custom electronics are advancing implantable drug delivery systems – with precise drug administration, seamless connectivity to other devices and real-time monitoring of drug levels and patient responses.

EFFICIENTLY PRODUCING INJECTABLES IN SMALL BATCHES

Klaus Brinkrode

EFFICIENTLY PRODUCING INJECTABLES IN SMALL BATCHES

Klaus Brinkrode and Ulrik Keldke discuss industry challenges in injectable production – and how to produce small batches of injection devices efficiently.

TRACE ANALYTICAL CONSIDERATIONS WHEN REFORMULATING pMDIS WITH NEXT-GENERATION LOW-GWP PROPELLANT SYSTEMS

TRACE ANALYTICAL CONSIDERATIONS WHEN REFORMULATING pMDIS WITH NEXT-GENERATION LOW-GWP PROPELLANT SYSTEMS

Mark Parry, John McLaughlin and Tino Otte discuss the necessary studies required to understand the nitrosamine formation and leachables profiles of new pMDI propellants with lower global warming potentials as part of the pharmaceutical industry’s drive to reduce its emissions and environmental impact.

ENVIRONMENTAL BENEFITS OF BEDSIDE IONIC NITRIC OXIDE GENERATION

ENVIRONMENTAL BENEFITS OF BEDSIDE IONIC NITRIC OXIDE GENERATION

David Webster and Mark Rimkus consider the environmental impact of traditional high-pressure storage systems for nitric oxide and highlight the benefits associated with bedside ionic generation.

FUTURE TRENDS FOR NOVEL INJECTABLE DRUG DELIVERY

Chris Hurlstone

FUTURE TRENDS FOR NOVEL INJECTABLE DRUG DELIVERY

Chris Hurlstone looks at the increasing demand for novel injectable devices and summarises the areas we can expect to see significant development activities in injectable technologies.

DEFINING HIGH-VISCOSITY, LARGE-VOLUME DRUG DELIVERY SYSTEMS

DEFINING HIGH-VISCOSITY, LARGE-VOLUME DRUG DELIVERY SYSTEMS

Kyle Toole, Blair Hutton and James McLusky discuss the value that mathematical modelling can provide in the early stages of injectable drug delivery device development, especially when coupled with appropriate empirical testing in a laboratory setting.

NAVIGATING THE AI REVOLUTION IN THE MEDICAL DEVICES SECTOR: BETWEEN INNOVATION AND REGULATION

NAVIGATING THE AI REVOLUTION IN THE MEDICAL DEVICES SECTOR: BETWEEN INNOVATION AND REGULATION

Timothy Bubb discusses the potential impact of artificial intelligence and machine learning on the healthcare and drug delivery industries, with an overview of the differing regulatory approaches taken by the EU, US FDA and UK MHRA towards this novel area of digital health.

SUSTAINABLE DESIGN FOR HEALTHCARE DEVICES: PATHWAYS TOWARDS NET ZERO

SUSTAINABLE DESIGN FOR HEALTHCARE DEVICES: PATHWAYS TOWARDS NET ZERO

Will Davies and Holly Milston consider sustainable pathways towards circularity in the medical device industry.

THE SPECIFIC APPROACH: THE ADVANTAGE OF CUSTOMISATION FOR WEARABLE DELIVERY SYSTEMS

Dave Beckstoffer

THE SPECIFIC APPROACH: THE ADVANTAGE OF CUSTOMISATION FOR WEARABLE DELIVERY SYSTEMS

Dave Beckstoffer considers how involving customisation from the outset of an on-body injector development project can not only optimise the patient outcome but also streamline the development timescale for device engineers, with a particular focus on the drive system.

MATERIAL SELECTION & EFFICIENT DEVELOPMENT PROCESSES FOR WEARABLE INJECTOR DRIVE SYSTEMS

Dave Beckstoffer

MATERIAL SELECTION & EFFICIENT DEVELOPMENT PROCESSES FOR WEARABLE INJECTOR DRIVE SYSTEMS

Dave Beckstoffer explains the importance of material selection in drive system development, the key attributes of materials towards a wearable and auto-delivery device, and discusses the need to achieve industrialisation based on material selection and relevant manufacturing processes.

USING EFFICIENT PROOF-OF-CONCEPT TESTS AND PILOT MOULDS FOR DEVICE DEVELOPMENT SUCCESS

USING EFFICIENT PROOF-OF-CONCEPT TESTS AND PILOT MOULDS FOR DEVICE DEVELOPMENT SUCCESS

Andreas Wild and Andreas Montag discuss the value of early proof-of-concept testing and sample production for drug delivery device development projects, with an emphasis on how partnership and consultation can smooth and enhance this process, including for design for automation and design for manufacturing considerations.

CLOSING THE LOOP: THE LATEST ON ARTIFICIAL PANCREAS SYSTEMS

Kamaal de Silva

CLOSING THE LOOP: THE LATEST ON ARTIFICIAL PANCREAS SYSTEMS

Kamaal de Silva looks at the future of closed-loop insulin delivery systems and how the management of Type 1 diabetes is developing in the digital era.

ADAPTING TO AN AGEING WORLD: FORMULATION STRATEGIES TO BOOST PATIENT COMPLIANCE

ADAPTING TO AN AGEING WORLD: FORMULATION STRATEGIES TO BOOST PATIENT COMPLIANCE

Jason Hunt and Yeli Zhang discuss the key factors undermining patient compliance in older adults and explore how the pharmaceutical industry can leverage excipients to enhance drug formulations and improve medication compliance among this critical demographic.

ARE ORAL FORMULATIONS OF OLIGONUCLEOTIDE THERAPEUTICS WITHIN REACH?

ARE ORAL FORMULATIONS OF OLIGONUCLEOTIDE THERAPEUTICS WITHIN REACH?

Nigel Theobald, discusses key issues and strategies for formulation scientists aiming to unlock the potential of oral delivery for small interfering ribonucleic acid drugs targeted against gastrointestinal diseases and cancers.

DIFFERENTIATING ORAL SUSPENSIONS WITH VERSATILE EXCIPIENTS

Mariona Venceslao Molins

DIFFERENTIATING ORAL SUSPENSIONS WITH VERSATILE EXCIPIENTS

Mariona Venceslao Molins and Liliana Miinea discuss how excipient-based approaches can facilitate patient-centric formulations and transform oral suspensions.

STRATEGIES TO MITIGATE GELATIN CROSS-LINKING IN ORAL SOLID DRUG DELIVERY

Dr Jnanadeva Bhat

STRATEGIES TO MITIGATE GELATIN CROSS-LINKING IN ORAL SOLID DRUG DELIVERY

Jnanadeva Bhat and Manali Dalvi discuss the factors contributing to gelatin cross-linking in oral solid dose delivery – and strategies to tackle the resulting challenges.

CANNABIDIOL DELIVERY THAT IS ON THE “TIP OF THE TONGUE”

Dr Zdravka Misic

CANNABIDIOL DELIVERY THAT IS ON THE “TIP OF THE TONGUE”

Zdravka Misic explores how formulation expertise can be applied to overcome the low bioavailability of cannabinoids and how innovation in orally disintegrating tablets is driving progress for cannabidiol-based therapeutics.

1
2
3
…
13
Next

Top